Q-omics provides the consensus-scored NF1 profile across patient tissues and cancer cell-line models. NF1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NF1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, NF1 RNA expression shows 21,301 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where NF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NF1 survival associations across molecular data types. NF1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (11) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NF1 RNA expression–survival associations across cancer types. High NF1 expression shows unfavorable associations in MESO, UVM, HNSC, ACC and BLCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NF1 RNA expression.
This table summarizes NF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NF1 shows higher tumor expression in HNSC, BLCA, LUAD, LIHC, CHOL and KIRP. The HNSC box plot shows higher NF1 RNA expression in tumor versus normal tissue (log2 FC = +0.994, t-test p < 0.001).
This table shows molecular features associated with NF1 in patient tissues and cancer cell lines. In patient samples, NF1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
